Published in Nat Commun on January 01, 2013
EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell (2014) 2.06
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
'N-of-1-pathways' unveils personal deregulated mechanisms from a single pair of RNA-Seq samples: towards precision medicine. J Am Med Inform Assoc (2014) 0.96
Mitotic phosphorylation of histone H3 threonine 80. Cell Cycle (2013) 0.88
Luteolin suppresses cancer cell proliferation by targeting vaccinia-related kinase 1. PLoS One (2014) 0.83
Proteomics Analysis with a Nano Random Forest Approach Reveals Novel Functional Interactions Regulated by SMC Complexes on Mitotic Chromosomes. Mol Cell Proteomics (2016) 0.83
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget (2016) 0.81
Lineage factors and differentiation states in lung cancer progression. Oncogene (2015) 0.81
Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response. Oncotarget (2014) 0.79
Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition. Oncotarget (2015) 0.78
Ursolic acid exerts anti-cancer activity by suppressing vaccinia-related kinase 1-mediated damage repair in lung cancer cells. Sci Rep (2015) 0.76
Development of a robust DNA quality and quantity assessment qPCR assay for targeted next-generation sequencing library preparation. Int J Oncol (2016) 0.75
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Empirical threshold values for quantitative trait mapping. Genetics (1994) 46.95
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics (2005) 24.04
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat Genet (2008) 5.80
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell (2010) 5.02
Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA (1997) 4.09
Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet (2005) 3.74
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res (2009) 3.72
A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res (2009) 3.50
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature (2011) 3.27
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J (2008) 2.95
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A (1994) 2.44
Validating Aurora B as an anti-cancer drug target. J Cell Sci (2006) 2.30
Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol (2010) 2.26
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res (2010) 2.02
Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem (2006) 2.00
Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet (2005) 1.97
Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res (2008) 1.96
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature (2009) 1.89
The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Oncogene (2000) 1.62
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol (2008) 1.61
Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase. Genomics (1997) 1.55
TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene (2008) 1.42
TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol (2009) 1.40
Human VRK1 is an early response gene and its loss causes a block in cell cycle progression. PLoS One (2008) 1.36
p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. Mol Cell Biol (2006) 1.26
Targeting Aurora-2 kinase in cancer. Mol Cancer Ther (2003) 1.23
Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer (2005) 1.13
Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol (1999) 1.11
NKX2-1 mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in "Brain-Lung-Thyroid Syndrome". Hum Mutat (2010) 1.11
Thyroid transcription factor in differentiating type II cells: regulation, isoforms, and target genes. Am J Respir Cell Mol Biol (2006) 1.09
Autosomal dominant transmission of congenital hypothyroidism, neonatal respiratory distress, and ataxia caused by a mutation of NKX2-1. J Pediatr (2004) 1.08
Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biol (2011) 1.08
Meta-analysis of inter-species liver co-expression networks elucidates traits associated with common human diseases. PLoS Comput Biol (2009) 0.99
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev (2007) 0.98
Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas. Lung Cancer (2007) 0.96
FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett (2009) 0.95
Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control. J Biol Chem (2008) 0.93
Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer (2008) 0.92
Regulation of human myoblast differentiation by PEBP4. EMBO Rep (2009) 0.91
MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines. Exp Dermatol (2005) 0.85
Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets (2006) 0.84
Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics. Mol Cancer Res (2008) 0.76
Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet (2003) 11.63
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A (2008) 3.71
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol (2002) 3.52
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res (2005) 2.81
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 2.69
Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet (2005) 2.51
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (2004) 2.41
Stem-cell hierarchy in skin cancer. Nat Rev Cancer (2003) 2.36
Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck (2008) 2.28
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet (2008) 2.05
Genome-wide detection of chromosomal imbalances in tumors using BAC microarrays. Nat Biotechnol (2002) 2.04
Genomic segmental polymorphisms in inbred mouse strains. Nat Genet (2004) 1.93
Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature (2009) 1.89
A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet (2006) 1.79
Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest (2007) 1.73
Mapping segmental and sequence variations among laboratory mice using BAC array CGH. Genome Res (2005) 1.71
Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res (2008) 1.62
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell (2007) 1.59
HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci U S A (2007) 1.58
Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56
Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature (2007) 1.54
Neonatal short bowel syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg (2004) 1.52
Structural and functional studies of LRP6 ectodomain reveal a platform for Wnt signaling. Dev Cell (2011) 1.50
CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res (2013) 1.48
A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res (2004) 1.44
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood (2011) 1.41
Early nodal response as a predictor for necessity of functional neck dissection after chemoradiation. Cancer J (2005) 1.38
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Comparison of cobinamide to hydroxocobalamin in reversing cyanide physiologic effects in rabbits using diffuse optical spectroscopy monitoring. J Biomed Opt (2010) 1.36
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. J Med Chem (2012) 1.35
The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol (2012) 1.33
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. J Thorac Oncol (2007) 1.32
A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A (2009) 1.32
Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes Dev (2004) 1.31
Stable prenucleation mineral clusters are liquid-like ionic polymers. Nat Commun (2011) 1.31
Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. J Allergy Clin Immunol (2013) 1.30
Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst (2012) 1.30
The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res (2010) 1.29
Genetic interactions between Pten and p53 in radiation-induced lymphoma development. Oncogene (2003) 1.28
Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res (2003) 1.27
Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest (2011) 1.25
Optimizing solute-water van der Waals interactions to reproduce solvation free energies. J Phys Chem B (2012) 1.25
Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. Cancer Cell (2011) 1.25
Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med (2011) 1.21
Keratin 16 regulates innate immunity in response to epidermal barrier breach. Proc Natl Acad Sci U S A (2013) 1.16
Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis. Mol Cancer Res (2012) 1.16
Integrin alphavbeta8-mediated activation of transforming growth factor-beta inhibits human airway epithelial proliferation in intact bronchial tissue. Am J Pathol (2003) 1.16
Cancer evolution and individual susceptibility. Integr Biol (Camb) (2011) 1.15
Bioresponsive mesoporous silica nanoparticles for triggered drug release. J Am Chem Soc (2011) 1.15
New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med (2007) 1.15
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun (2012) 1.13
Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med (Berl) (2012) 1.12
Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr (2014) 1.12
Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. J Invest Dermatol (2004) 1.11
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol (2010) 1.10
Insulin stimulates Akt translocation to mitochondria: implications on dysregulation of mitochondrial oxidative phosphorylation in diabetic myocardium. J Mol Cell Cardiol (2009) 1.09
Genomic approaches to identification of tumour-susceptibility genes using mouse models. Curr Opin Genet Dev (2003) 1.08
Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biol (2011) 1.08
Clinical, radiological, and manometric profile in 145 patients with untreated achalasia. World J Surg (2008) 1.07
Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet (2009) 1.06
CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR. Mol Cancer (2014) 1.06
Irradiation of juvenile, but not adult, mammary gland increases stem cell self-renewal and estrogen receptor negative tumors. Stem Cells (2014) 1.05
Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. Mol Cancer Res (2012) 1.05
p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene (2005) 1.04
A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.04
Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg (2007) 1.03
Wnt and hedgehog gene pathway expression in serous ovarian cancer. Int J Gynecol Cancer (2011) 1.02
Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. Cancer Res (2011) 1.01
Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility. PLoS One (2012) 1.00